Current treatment of metastatic endometrial cancer.

Cancer Control. 2009 Jan;16(1):38-45

Authors: Temkin SM, Fleming G

BACKGROUND: Endometrial cancer is the most common gynecologic malignancy. The majority of patients have disease confined to the uterus and have an excellent overall prognosis. However, subgroups of patients have advanced primary disease or recurrences following primary treatment.

Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer.

Cancer Control. 2009 Jan;16(1):53-6

Authors: Allard JE, Maxwell GL

BACKGROUND: Uterine cancer is the most common gynecologic malignancy in the United States, with an estimated 40,100 new cases and 7,470 deaths occurring in 2008. Although the incidence of endometrial cancer is lower among black women compared with white women, the proportion of cancer-related deaths among blacks is higher and has continued to rise over the past two decades.

The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.

Cancer Control. 2009 Jan;16(1):8-13

Authors: Bansal N, Yendluri V, Wenham RM

BACKGROUND: Understanding and identifying molecular biology and genetics of endometrial cancer are central to the development of novel therapies. This article reviews the molecular basis for genesis of endometrial cancer with regard to pathogenesis, classification, and implications for targeted therapies.

Will patients benefit from regionalization of gynecologic cancer care?

PLoS One. 2009;4(1):e4049

Authors: Brookfield KF, Cheung MC, Yang R, Byrne MM, Koniaris LG

OBJECTIVE: Patient chances for cure and palliation for a variety of malignancies may be greatly affected by the care provided by a treating hospital. We sought to determine the effect of volume and teaching status on patient outcomes for five gynecologic malignancies: endometrial, cervical, ovarian and vulvar carcinoma and uterine sarcoma.